El Monte, CA, United States of America

Teresa Hong

This inventor holds 1 USPTO granted patent. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Teresa Hong. Retrieved from https://idiyas.com/inventor/teresa-hong

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Teresa Hong and Proliposomal Testosterone Undecanoate Formulations.

Introduction

Teresa Hong is an inventor associated with El Monte, California, United States. Her patent work concerns proliposomal formulations of testosterone undecanoate, a pharmaceutical compound.

Latest Patents

The provided information identifies one patent for Hong: “Proliposomal Testosterone Undecanoate Formulations.” The invention describes powder dispersions combining testosterone undecanoate (TU) with phospholipids. Examples include TU and dipalmitoylphosphatidylcholine (DPPC) at an approximate 1:2 weight ratio, and TU with DMPC or MPPC at approximate 1:3 weight ratios. These formulations are designed as proliposomal dispersions.

Career Highlights

Hong’s listed patent record reflects work on pharmaceutical formulation technology. Her contribution focuses on specified combinations and proportions of testosterone undecanoate and phospholipids. The supplied information lists 1 patent.

Collaborations

The provided data names Veeran Gowda Kadajji and Guru V. Betageri as Hong’s coworkers associated with this invention.

Conclusion

Teresa Hong’s listed invention addresses proliposomal testosterone undecanoate formulations through defined phospholipid combinations and ratios.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…